Alios BioPharma (San Francisco, CA) a pre-clinical biotechnology company developing small molecule activators of innate immunity antiviral pathways, closed a $8.4M Series A financing. Participants include Novo A/S, Novartis BioVentures and Roche Venture Fund.

Okapi Sciences (Belgium) early-stage developer of antiviral drugs for veterinary applications, closed a $10.8M Series A financing. Participants include Agri Investment Fund, Dutch Thuja Capital, Fortis Private Equity Arkimedes, KBC Arkiv, Vinnof, Gemma Frisius Fund, K.U.Leuven and Spinventure.

Chimerix (Seattle, WA) is applying its technology to the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection, viral hepatitis, and macular degeneration, has closed $23.1M in Series D funding. Canaan Partners led the deal, and was joined by Alta Partners and return backers Sanderling Ventures, Asset Management Company and Frazier Healthcare Ventures.